New MO for Purported Anti-Amyloid Drug: Shielding APP from BACE?
Imatinib, previously reported to inhibit γ-secretase, now appears to isolate APP from BACE as well.
ALL NEWS
5723 RESULTS
Sort By:
Global Genetics Symposium Starts Today
Three weeks of on-demand seminars to culminate in live Q&A.
Does Second X Chromosome Boost Women’s Resilience Against Alzheimer’s?
In female mice it’s the other X chromosome, not lack of a Y, that extends life and preserves memory in the face of amyloidosis. A histone demethylase gene partly explains this. It protects people, too.
Philadelphia: Can a Shrinking Brain Be Good for You?
Perhaps…yes? At first blush, this is the tentative conclusion one must draw if the results of presentations yesterday on Elan's vaccine...
Rogue APP Claim Embroiled in Contamination Concerns
A 2018 report that had spotted extra copies of APP lurking in neuronal genomes has come under scrutiny, with claims that the result is due to contamination. Does a response from the original authors bolster their claim?
Molecular Structure of LRRK2 Gives Clues to Parkinson’s
The first high-resolution look at LRRK2 implies that pathogenic mutations increase binding to microtubules by biasing the kinase domain toward a closed, active conformation.
In ALS and FTD, Two Different Routes to TDP-43 Aggregation
A C9ORF72 polydipeptide repeat induces aggregation by direct interaction with TDP-43, while progranulin mutations that trigger microglial toxicity cause TDP-43 to accumulate via complement.
First Round of FTD Therapeutics Fell Short, But Many More Are Up and Running
Researchers reported negative findings from three trials at ICFTD 2016.
Mutation in the Parkinson’s Gene DJ-1 Derails Splicing
Restoring proper gene editing assuaged mitochondrial defects in patient-derived neurons and organoids. Splicing errors may underlie other PD cases as well.
IFITM3 Forges Link Between Neuroinflammation and Aβ Production
The antiviral protein enhances γ-secretase processing of APP. More of it is present in Alzheimer’s disease.
In Preclinical Alzheimer’s, Learning Falters Before Memory
Learning tests may prove more informative in clinical trials of early AD. A new one claims it can spot a difference in six days.
Paris: More Trial News, Mixed at Best
With the buzz surrounding amyloid-targeting therapies, it is easy to lose sight of the fact that other treatments are being tested as well...
At AAIC, Encouraging Safety Data on a Variety of Small-Molecule Candidates
Three BACE inhibitors, a γ-secretase modulator, and a phosphodiesterase inhibitor appeared safe in Phase 1 trials.
11th ICFTD Meeting in Sydney Sorts Out Clinical Subtypes
Can genetics please parse the confusing spectrum of frontotemporal dementias? Whole genome sequences make a start.
Searching for New AD Risk Variants? Move Beyond GWAS
At AAIC 2017, researchers presented new approaches to find genetic variants linked to AD risk and to understand their contributions to disease.
Current Filters
- Date Range : All x